New tumor-associated antigen SC6 in pancreatic cancer

Min-Pei Liu, Xiao-Zhong Guo, Jian-Hua Xu, Di Wang, Hong-Yu Li, Zhong-Min Cui, Jia-Jun Zhao, Li-Nan Ren

AIM: To examine the concentration of a new antigen SC6 (SC6-Ag) recognized by monoclonal antibody (MAb) in patients with pancreatic cancer and other malignant or benign diseases and to understand whether SC6-Ag has any clinical significance in distinguishing pancreatic cancer from other gastrointestinal diseases.

METHODS: Six hundred and ninety-five serum specimens obtained from 115 patients with pancreatic cancer, 154 patients with digestive cancer and 95 patients with non-digestive cancer were used and classified in this study. Serum specimens obtained from 140 patients with benign digestive disease and 89 patients with non-benign digestive disease served as controls. Ascites was tapped from 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer patients, 154 patients with pancreatic cancer from other gastrointestinal diseases.

RESULTS: The average intra- and interassay CV detected by immunoradiometric assay of SC6-Ag was 5.4% and 8.7%, respectively. The sensitivity and specificity were 73.0% and 90.9% respectively. The levels in most malignant and benign cases were within the normal upper limit. Among the 16 pancreatic cancer cases, the concentration of SC6-Ag in ascites was over the normal upper limit. Among the 16 pancreatic cancer patients, 19 hepatic cancer patients, 16 colonic cancer patients, 10 gastric cancer patients and 6 severe necrotic pancreatitis patients. The samples were quantitated by solid-phase radioimmunoassay. The cut-off values (CV) of 41, 80, and 118 U/mL were used.

CONCLUSION: The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer. The detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Tumor antigen SC6; Pancreatic neoplasm; Immunoradiometric assay

Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN. New tumor-associated antigen SC6 in pancreatic cancer. World J Gastroenterol 2005; 11(48): 7671-7675
http://www.wjgnet.com/1007-9327/11/7671.asp

INTRODUCTION

Pancreatic cancer is the fourth or the fifth leading cause of cancer-related deaths in the Western world[1-5]. Approximately 50% of pancreatic cancer patients have metastatic disease at the time of diagnosis with a median survival of 3-6 mo[6-8]. However, even 70-80% of patients, whose tumor could be completely removed, suffer from an incurable local relapse, distant metastases, or peritoneal carcinosis[6,8]. The overall 5-year survival rate of pancreatic cancer patients is only 1%[6,7]. Ultrasound, computer tomography (CT), magnetic resonance imaging and other methods have made it easier to define the late-stage disease and to establish its diagnosis. Unfortunately, these imaging and diagnostic methods cannot detect the early-stage disease[8,9].

In recent years, there has been an increasing clinical attention to the role of tumor markers in the pathogenesis of pancreatic cancer[10-14]. The most widely used marker for pancreatic cancer is CA19-9[15-18]. CA19-9 has a mean sensitivity of 81% and a mean specificity of 90% for pancreatic cancer[19,20]. Other mucin-type markers such as CA50, CA242, DU-PAN2, CA195 and CAM17.1/WGA have also been described for pancreatic cancer[24-26]. These markers have been investigated less widely than CA19-9 but available evidence appears to provide similar data[29-33]. CA19-9 remains as the "gold standard marker"[19] against which tumor markers for pancreatic cancer are evaluated.

Antigen SC6 (SC6-Ag) recognized by monoclonal antibody SC6 (MAb SC6) against human colonic cancer is a relatively new marker compared with CA19-9, CA242, CEA, AFP, DU-PAN-2 and β-MG[24-28]. The antigen was purified by immuno-affinity chromatography using the MAb SC6 at our laboratory. The results of SDS-
Purified antigen SC6 from human colonic cancer tissues as MAb SC6 is a murine MAb of the IgG1 isotype against the ascitic fluid of BALB/C mice in which hybridoma cell line SC6 was injected intraperitoneally and purified by protein A-Sepharose 4B columns (Bioinstitute, Shanghai, China). Normal murine immunoglobulin (IgG1, Bioinstitute, Beijing, China) was used as nonspecific control antibody. The MAb was labeled with Na\(^{125}\)I by the iodogen method. The average intra- and interassay CV of the method was 5.4% and 8.7% respectively. The recovery rate was 96.5-108.0%, average 102.3%.

**MATERIALS AND METHODS**

**Patients**

Serum specimens were obtained from 115 patients with pancreatic cancer (41 females and 74 males, mean age 61 years, with a range of 39-80 years). Among them, 39 had well- and moderately-differentiated tumor, 55 had poorly-differentiated tumor and 21 had differentiated tumor with unknown reason. According to International Union Against Cancer criteria, 9 patients had stage I disease, 33 stage II, 46 stage III and 6 stage IV. Fifteen primary esophageal cancer specimens, 43 gastric cancers specimens, 11 specimens of cancer of papilla of Vater, 39 hepatocellular carcinoma specimens and 46 colonic cancer specimens were classified. Fifteen esophagitis patients (5 females and 10 males; mean age 41 years), 27 gastritis patients (11 females and 16 males; mean age 38 years), 16 papilla of Vater cancer patients (7 females and 9 males; mean age 43 years), 28 pancreatitis patients (15 females and 13 males; mean age 35 years), 23 cirrhosis patients (10 females and 13 males; mean age 44 years) and 31 colitis patients (17 females and 14 males; mean age 35 years) were obtained. The diagnosis of pancreatic cancer was made based on histology and clinical and radiological findings. We noted weight loss, duration of symptoms and tumor position. Other cancers were diagnosed by abdominal ultrasound and CT scan, surgery, pathology and expressed as mean±SD. The SC6-Ag concentration in sera of controls was lower than CV. The CV of 41 U was mean±2SD, 80 U was mean±3SD, 118 U was mean±4SD. CA 19-9 kit (Abbott Diagnostics, USA) was quantitated by solid-phase radioimmunoassay, CV of 37 U/mL were used.

**Statistical analysis**

Analysis was performed using SPSS 10.0 software package. For the comparison of various tumor markers, CV representing 90% and 95% specificity levels in patients with relevant benign diseases were determined. The correlation between SC6-Ag and CA 19-9 concentrations was calculated by linear regression using the logarithms of the serum levels. The statistical comparison of multifactors was made and results were significant (P<0.05).

**RESULTS**

**SC6-Ag levels in pancreatic cancer and other diseases**

The characteristics of the 695 patients are presented in Table 1. Low concentration SC6-Ag was found in the sera from 102 healthy individuals and the cut-off of its normal upper limit was 41 U/mL (20.7±9.8). Among the 115 patients with pancreatic cancer, the cut-off was over the normal range in 73.3% patients, more than 118 U/mL in 48.7% patients and over 41 U/mL in 29.9% patients. The SC6-Ag level was mainly elevated in colonic cancer, hepatic carcinoma and gall bladder tract/bile duct cancers. Non-digestive cancers were mainly non-small cell lung cancer and renal carcinoma. Lower levels of SC6-Ag were observed in benign digestive and non-digestive diseases.
DISCUSSION

It is obvious that early diagnosis has the greatest impact on the survival of patients with pancreatic cancer. Clinically, fast spiral CT using dynamic intravenous contrast and the potential for improved MRI can provide high-resolution images of small masses\cite{9-13}. Endoscopic retrograde cholangiopancreatography with improved cytology, brushes, and biopsy forceps should enhance preoperative diagnosis of this malignancy. Endoscopic ultrasound also may help detect small lesions and determine the depth of invasion and vascular involvement. Tumor markers are normally produced in low quantities by cells in the body. Detection of a higher serum level of tumor markers by radioimmunoassay or immunohistochemical techniques usually indicates the presence of a certain type of cancer. In some types of cancer, tumor marker levels may reflect the extent or stage of the disease and can be useful in its diagnosis. Recently, the most widely used marker for pancreatic carcinoma is CA19-9, but SC6-Ag has also been found in China\cite{34-38}.

In the present study, high levels of SC6-Ag over the normal upper limit (41 U/mL) were found in 73.0% patients with pancreatic cancer, and in 29.8% patients with other digestive tumors. Using a cut-off point of 80 U/mL, the proportion of patients with elevated levels was 59.2%. But over 118 U/mL SC6-Ag was detected in 48.7% patients with pancreatic cancer, in 5.8% patients with digestive cancers, in 4.2% patients with non-digestive carcinomas and in 2% patients with benign digestive diseases. Furthermore, patients with certain benign diseases such as jaundice and pancreatitis, may present with elevated levels of CA19.9\cite{12-14}, suggesting that SC6-Ag and CA19-9 may have similar value in the diagnosis of pancreatic cancer.

Increased SC6-Ag concentrations in ascites are not specific for adenocarcinoma of the pancreas when the CV is 41 U/mL, which was evaluated in other digestive tumors and pancreatitis in our study (Table 2). With a cut-off point of 118 U/mL, the respective specificities for patients with pancreatic cancer were high compared to patients with gastric cancer or pancreatitis, indicating that high SC6-Ag level can be used to distinguish pancreatic cancer from benign disorders. However, decreased level of SC-Ag in pancreatic head compared to that in its body and tail failed to reach statistical significance (P>0.05).


### Table 1 SC6-Ag levels in patients with malignant and benign disease

| Groups               | Cases | >41 U/mL | >80 U/mL | >118 U/mL | n (%) | n (%) | n (%) |
|----------------------|-------|----------|----------|-----------|-------|-------|-------|
| Control              | 102   | 7 (6.9)  | 2 (2.0)  | 0 (0.0)   |       |       |       |
| Pancreatic Ca        | 115   | 84 (73.0)| 68 (59.1)| 56 (48.7) |       |       |       |
| Digestive Ca         | 154   | 46 (29.9)| 24 (15.6)| 11 (7.1)  |       |       |       |
| Non-digestive Ca     | 95    | 11 (11.6)| 8 (8.4)  | 4 (4.2)   |       |       |       |
| Benign digestive     |       |          |          |           |       |       |       |
| Diseases             | 140   | 13 (9.3) | 9 (6.4)  | 2 (1.4)   |       |       |       |
| Non-benign digestive | 89    | 8 (9.0)  | 4 (4.5)  | 0 (0.0)   |       |       |       |

### Table 2 SC6-Ag concentration in ascites from patients with different digestive diseases (mean±SD)

| Groups      | Cases | SC6-Ag (U/mL Concentration) | >41 | >80 | >118 | n (%) | n (%) | n (%) |
|-------------|-------|-----------------------------|-----|-----|------|-------|-------|-------|
| Pancreatic Ca| 16    | 120±910.9                   | 15  | 11  | 7    |       |       |       |
| Hepatic Ca   | 19    | 55±33.4                     | 10  | 3   | 1    |       |       |       |
| Colonic Ca   | 16    | 54±26.7                     | 9   | 4   | 1    |       |       |       |
| Gastric Ca   | 10    | 38±23.4                     | 3   | 1   | 0    |       |       |       |
| Several pancreatitis | 6  | 30.9±26.3                   | 2   | 0   | 0    |       |       |       |

### Table 3 Comparison of parameters for SC6-Ag, CA19-9, ultrasound and CT in patients with pancreatic cancer

|                | SC6-Ag (%) | CA19-9 (%) | Ultrasound (%) | CT (%) |
|----------------|------------|------------|----------------|--------|
| Sensitivity    | 73.0 (84/115)| 84.3 (97/115)| 82.6 (95/115)| 83.5 (96/115) |
| Specificity    | 90.9 (70/77)| 84.4 (65/77)| 55.8 (43/77)| 59.7 (46/77)  |
| Positive predictive value | 92.3 (84/91)| 88.5 (92/104)| 73.8 (96/130)| 76.2 (99/130) |
| Negative predictive value | 69.3 (70/101)| 73.9 (65/88)| 69.4 (43/62)| 74.2 (46/62)  |

Relationship between SC6-Ag and clinicopathological factors

SC6-Ag was not significantly related with clinicopathological factors in patients with pancreatic cancer. Decrease of SC6-Ag in the pancreatic head was compared with that in its body and tail. However, the difference failed to reach statistical significance (P>0.05).

SC6-Ag concentration in ascites from patients with different digestive diseases

Among the 16 patients with pancreatic cancer, the concentration of SC6-Ag in ascites was over the normal range in 93.8% patients, over 41 U/mL in 33.3-52.6% patients and more than 118 U/mL in 43.8% patients (Table 2).

Parameters for SC6-Ag, CA19-9, ultrasound and CT in patients with pancreatic cancer

The sensitivity of SC6-Ag and CA19-9 was similar to that of ultrasound and CT, while the specificity of SC6-Ag and CA19-9 was significantly higher than that of ultrasound and CT in patients with pancreatic cancer. Higher positive predictive values were found in 92.3% SC6-Ag and 88.5% CA19-9, but lower positive predictive values were found in 73.8% ultrasound and 76.2% CT (Table 3).
In the recent study, the sensitivity, specificity and positive predictive value of SC6-Ag were found to be 73.0%, 90.9% and 92.3%, respectively. By analyzing the four factors, we found that the sensitivity of SC6 and CA19-9 was lower than that of ultrasound and CT, but their specificity was significantly higher (Table 3). Positive predictive values in SC6-Ag and CA19-9 were 92.3% and 88.5%, which were distinctly higher than those of ultrasound (73.8%) and CT (76.2%). The lack of sensitivity and specificity also limits the diagnosis of pancreatic cancer although CA19-9 and SC6-Ag may be useful in differentiating benign from malignant pancreatic disease in non-jaundiced patients. However, combined measures are more useful in the diagnosis of pancreatic cancer.

In conclusion, detection of SC6-Ag is valuable in the diagnosis of pancreatic cancer before and after surgery. The combined test of SC6-Ag and CA19-9 may improve the diagnostic rate of primary cancer.

REFERENCES

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47
2. Liu MP, Ma JY, Pan BR, Ma LS. Study of pancreatic cancer in China. Shijie Huaren Xinhua Zazhi. 2001; 9: 1103-1109
3. Rocha Lima CM, Centeno B. Update on pancreatic cancer. Curr Opin Oncol. 2002; 14: 424-430
4. Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas. 2004; 28: 263-267
5. Iacobuzio-Donahue CA, Hruban RH. Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. Adv Anat Pathol. 2003; 10: 125-134
6. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000; 7: 421-427
7. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951-955; discussion 955-956
8. Cohen-Salci F, Vilgrain V, Brancatelli G, Hamlot P, Vullierme MP, Sauvanet A, Menu Y. Discrimination of unilocular macrocystic serous cystadenoma from pancreatic pseudocyst and mucinous cystadenoma with CT: initial observations. Radiology 2003; 228: 727-733
9. Zhao XY, Yu SY, Da SP, Bai L, Guo XZ, Dai XJ, Wang YM. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 1998; 4: 147-149
10. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16: 37-52
11. Furukawa H. Diagnostic clues for early pancreatic cancer. Ipn J Clin Oncol 2002; 32: 391-392
12. Bassi C, Salvia R, Gumbs AA, Butturini G, Falconi M, Pedzeroli P. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, CA 19-9, CA 125, CA 15-3, CA 15-3. Langenbecks Arch Surg 2002; 387: 281-285
13. Carpelan-Holmström M, Louhimo J, Stennan UH, Alfttan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2511-2316
14. Schneider J, Schulze G. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003; 23: 5099-5093
15. Cmogorac-Jurcovic T, Missiaglia E, Blaveri E, Gangswarans R, Jones M, Terris B, Costello E, Neoptolemos JP, Lemoine NR. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 2003; 201: 63-74
16. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamashita S, Chayama K. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003; 26: 344-349
17. Akashi T, Omomi H, Nishiyama K, Nakashima M, Arita Y, Sumii T, Kimura T, Ito T, Nawa H, Watanabe T. Expression and diagnostic evaluation of the human tumor-associated antigen RCASI in pancreatic cancer. Pancreas 2003; 26: 49-55
18. Ji I, Isacson C, Seidman JD, Kurnj RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Cancer Pathol 2002; 21: 391-400
19. Palumbo KS, Wands JR, Safran H, King T, Carlson RL, de la Monte SM. Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas 2002; 25: 39-44
20. Mizumoto K, Tanaka M. Genetic diagnosis of pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 39-44
21. Ghanem P, Kavoush A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002; 9: 1-11
22. Biltze C, Schneider-Stock R, Aust G, Mawrin C, Drale H, Roessner A, Hoang-Vu C. CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of curotomy sections. Pathol Int 2002; 52: 83-88
23. Maacke H, Hundertmark C, Miska S, Voss M, Kalthoff H, Stürzbecher HW. Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol 2002; 128: 219-222
24. Tempia-Caliera AA, Horvath LZ, Zimmermann A, Tihanyi TT, Korc M, Friess H, Büchler MW. Adhesion molecules in human pancreatic cancer. J Surg Oncol 2002; 79: 93-100
25. Künzli BM, Berberat PO, Zhu ZW, Martignoni M, Kleef J, Tempia-Caliera AA, Fukuda M, Zimmermann A, Friess H, Büchler MW. Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer 2002; 94: 228-239
26. Gerdes B, Ramaswamy A, Ziegler A, Lang SA, Kersting M, Baumann R, Wild A, Moll R, Rothmund M, Bartsch DS. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg 2002; 235: 51-59
27. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, Kim YS. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraperithelial neoplasms of the pancreas. Gastroenterology 2002; 123: 1052-1060
28. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hino Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103: 97-100
29. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997; 349: 389-392
30. Levi E, Klimstra DS, Andea A, Basturk O, Adsay V, N. V. CUMC and MUC2 in pancreatic neoplasia. J Clin Pathol 2004; 57: 456-462
31. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004; 35: 357-366
32. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M. Evaluation of osteopontin as biomarker for pancreatic cancer.
adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 2004; 13: 487-491

33 **Grützmann R**, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schackert HK, Saeger HD, Kloppel G, Pilarsky C. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. *Br J Cancer* 2004; 90: 1053-1058

34 **Liu MP.** Characteristics and reactivities of a panel of monoclonal antibodies (McAbs) recognizing human colon cancer associated antigens. *Zhonghua Zhongliu Zazhi* 1992; 14: 91-93

35 **Liu MP.** Immunohistochemical analysis of physicochemical properties of target antigens with anti-tumor monoclonal antibodies. *Zhonghua Zhongliu Zazhi* 1992; 14: 6-9

36 **Liu MP.** Zhou JC, Guo XZ, Chen W, Dai B, An TY, Ma SY. Purification and characterization of antigen SC6 for pancreatic cancer. *Shijie Huaren Xiaohua Zazhi* 1999; 7: 593-595

37 **Guo XZ.** Liu MP, Li XX. Evaluation of serum antigen SC6 using immunoradiometric assay for diagnosis of pancreatic cancer. *Zhonghua Neike Zazhi* 1992; 31: 84-86

38 **Guo XZ.** Liu ZF, An R, Zhao XL, Li FH, Wang KG. Antigen SC6 for the diagnosis of pancreatic cancer before operation. *Zhonghua Yixue Zazhi* 1993; 73: 26-28

Science Editor Wang XL and Guo SY Language Editor Elsevier HK